Travere Therapeutics appoints Bradley L. Campbell CEO effective Dec. 1, 2026
CEO Eric Dube will step down; Bradley L. Campbell appointed president and CEO effective Dec. 1, 2026. Dube will serve as executive advisor through Feb. 15, 2027.
CEO Eric Dube will step down; Bradley L. Campbell appointed president and CEO effective Dec. 1, 2026. Dube will serve as executive advisor through Feb. 15, 2027.